NEW YORK, NY - January 13, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Beta Bionics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.
Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas, an automated insulin delivery system. According to the Company’s press release dated January 8, 2026, “[t]he iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose.”
On January 8, 2026, after markets closed, Beta Bionics announced its preliminary, unaudited topline financial results and key metrics for the fourth quarter of 2025. The Company reported “[n]ew patient starts expected to be at least 5,581” for the fourth quarter of 2025. An analyst at Bloomberg reportedly stated that “Beta’s 5,581 new-patient starts fell short of the 6,078 consensus expectation.” An analyst at Leerink Partners reportedly stated that “the -4% miss for new customer starts (NCS) may be a source of near-term volatility for the stock.”
Following this news, on January 9, 2026, the price of Beta Bionics stock declined from a closing price on January 8, 2026 of $31.99 per share, to close at $20.14 per share, a decline of $11.85 per share, or by 37%.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
View the original release on www.newmediawire.com
